Burger - Figure 42
Sarcomatoid Carcinoma
FIG. 42: Plasmacytoid carcinoma is very rare, comprising about 0.1% of all bladder cancer cases.[7,25,26] As a result the evidence comes mainly from case reports, which suggest that the outcome is markedly worse in these cases compared with classical urothelial carcinoma. Radical cystectomy and adjuvant chemotherapy have been suggested as therapy of choice, but the median overall survival is around 27% without chemotherapy and about 60% with adjuvant chemotherapy,[26] and data are scarce.
References
Klaile Y, Schlack K, Boegemann M, et al. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol. 2016;5:692−701 https://dx.doi.org/10.21037%2Ftau.2016.06.13
Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol. 2014;32:833−8 http://dx.doi.org/10.1016/j.urolonc.2014.03.008
Keck B, Wach S, Stoehr R, et al. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. 2013;13:71 https://doi.org/10.1186/1471-2407-13-71
